In summary, the preclinical studies and clinical trials on PD-1/PD-L1 blockade combination with other ICBs in cancer therapy have been summarized in Table 1A, B, C, D and Table 2A, B, C, D, showing synergistic anti-tumor efficacy to some extent. Here, CD274 is linked to neoplasm.